Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc (AMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,643,142
  • Shares Outstanding, K 314,363
  • Annual Sales, $ 2,794 M
  • Annual Income, $ -116,890 K
  • EBIT $ 358 M
  • EBITDA $ 623 M
  • 60-Month Beta 1.36
  • Price/Sales 1.58
  • Price/Cash Flow 10.39
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 114.71% (+5.94%)
  • Historical Volatility 24.62%
  • IV Percentile 87%
  • IV Rank 65.47%
  • IV High 173.90% on 12/08/25
  • IV Low 2.47% on 09/09/25
  • Expected Move (DTE 13) 1.73 (11.94%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 392
  • Volume Avg (30-Day) 216
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 8,991
  • Open Int (30-Day) 8,069
  • Expected Range 12.79 to 16.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.16
  • Number of Estimates 2
  • High Estimate 0.17
  • Low Estimate 0.14
  • Prior Year 0.10
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.66 +14.69%
on 01/13/26
15.00 -3.20%
on 01/29/26
+1.53 (+11.78%)
since 01/06/26
3-Month
11.29 +28.56%
on 11/07/25
15.00 -3.20%
on 01/29/26
+2.86 (+24.53%)
since 11/06/25
52-Week
6.68 +117.37%
on 04/10/25
15.00 -3.20%
on 01/29/26
+6.55 (+82.18%)
since 02/06/25

Most Recent Stories

More News
3 Small-Cap Stocks That Fall Short

3 Small-Cap Stocks That Fall Short

AD : 48.75 (+0.70%)
AMRX : 14.52 (-1.69%)
WD : 63.23 (+0.59%)
3 Cash-Producing Stocks That Concern Us

3 Cash-Producing Stocks That Concern Us

PVH : 66.12 (+2.34%)
STNG : 68.43 (+4.63%)
AMRX : 14.52 (-1.69%)
3 Healthcare Stocks We Steer Clear Of

3 Healthcare Stocks We Steer Clear Of

NVAX : 8.25 (+4.83%)
AMRX : 14.52 (-1.69%)
DVA : 140.83 (-5.62%)
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600 ®...

AMRX : 14.52 (-1.69%)
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

NEW YORK , Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600:

CADE : 42.11 (-1.66%)
HBAN : 19.27 (+1.31%)
CIVI : 27.38 (-1.37%)
RYN : 22.46 (-0.27%)
APLS : 23.49 (+4.12%)
AHR : 48.77 (+1.25%)
BROS : 57.04 (+8.81%)
AMRX : 14.52 (-1.69%)
LZ : 8.05 (+3.07%)
AEIS : 273.26 (+6.06%)
FITB : 55.08 (+2.40%)
PCH : 41.73 (+0.05%)
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter...

AMRX : 14.52 (-1.69%)
2 Reasons to Sell AMRX and 1 Stock to Buy Instead

2 Reasons to Sell AMRX and 1 Stock to Buy Instead

AMRX : 14.52 (-1.69%)
Can This Healthcare Stock Keep Going After a Nearly 70% Surge?

Amneal Pharmaceuticals (AMRX) is trading at new 5-year highs with strong technical momentum. AMRX has gained 69% over the past year. Shares maintain a 100% “Buy” technical opinion on Barchart. Analyst...

AMRX : 14.52 (-1.69%)
1 Profitable Stock with Exciting Potential and 2 Facing Headwinds

1 Profitable Stock with Exciting Potential and 2 Facing Headwinds

ULH : 18.04 (-0.61%)
EME : 764.35 (+6.50%)
AMRX : 14.52 (-1.69%)
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

Approvals expand Amneal’s biosimilars portfolio Company expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal...

AMRX : 14.52 (-1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories...

See More

Key Turning Points

3rd Resistance Point 15.34
2nd Resistance Point 15.16
1st Resistance Point 14.84
Last Price 14.52
1st Support Level 14.35
2nd Support Level 14.17
3rd Support Level 13.85

See More

52-Week High 15.00
Last Price 14.52
Fibonacci 61.8% 11.82
Fibonacci 50% 10.84
Fibonacci 38.2% 9.86
52-Week Low 6.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar